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Abstract  1 
 2 
Purpose: In Caco-2 cells, folate uptake via the proton-coupled folate transporter (PCFT) increases 3 
significantly by a three-day treatment with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Additionally, 4 
mRNA content and protein expression of the transporter OATP1A2 was increased up to 9-fold with 5 
1,25(OH)2D3. We investigated whether these in vitro findings can be confirmed in humans in vivo.  6 
Methods: Ten healthy volunteers (6 women) received 5 mg folic acid orally once before and once 7 
together with the last intake of a ten-day course of 0.5 µg 1,25(OH)2D3 orally. 120 mg fexofenadine, an 8 
OATP1A2 substrate, were taken in one day before the first folic acid intake, and again on the ninth 9 
day of 1,25(OH)2D3 intake. Duodenal biopsies were taken for transporter mRNA assessments once 10 
before and once on the ninth or tenth day of the vitamin D3 course. Serum folic acid and fexofenadine 11 
concentrations were quantified with a chemiluminescence immunoassay and LC-MS/MS, respectively. 12 
Pharmacokinetics were compared between periods with standard bioequivalence approaches.  13 
Results: While geometric mean folic acid AUC0-2h, which mainly reflects absorption, was 0.403 and 14 
0.414 mg/L*h before and after the vitamin D3 course (geometric mean ratio (GMR): 1.027, 90% 15 
confidence interval (90%CI): 0.788-1.340), the geometric mean fexofenadine AUC0-2h was 1.932 and 16 
2.761 mg/L*h, respectively (GMR: 1.429, 90%CI: 0.890-2.294). PCFT- and OATP1A2-mRNA 17 
expressions in duodenal biopsies were essentially unchanged.  18 
Conclusions: No significant changes in folic acid and fexofenadine absorption were observed after a 19 
ten-day course of 1,25(OH)2D3 in humans in vivo. This study underlines the importance of confirming 20 
in vitro findings in vivo in humans.  21 
 22 
Keywords  23 
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Introduction  1 
 2 
The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), exerts most effects, e.g. on 3 
calcium homeostasis, via binding to vitamin-D receptors (VDR) in the cell nucleus. As a heterodimer 4 
with the retinoid-X-receptor α (RXR), VDR regulates the transcription of numerous genes [1], like 5 
cytochrome P450 24A1, which is involved in 1,25(OH)2D3 biodegradation, tryptophan hydroxylase 2 in 6 
the brain [2], the organic anion transporting polypeptide 1A2 OATP1A2 [3] or the folate uptake 7 
transporter PCFT [4]. However, evidence for the role of 1,25(OH)2D3 in the functional regulation of 8 
these proteins usually comes from in vitro or animal experiments, and the relevance in humans is 9 
unknown.  10 
 11 
The water soluble vitamin folic acid is the precursor for the production of the metabolically active 12 
folates, which are essential for the synthesis of nucleic acids in human cells. Naturally occurring 13 
folates in food are conjugated to a polyglutamyl chain which is removed by the enzyme folate 14 
conjugase in the mucosal cells before the folate monoglutamates can be absorbed in the duodenum 15 
and jejunum [5] mainly by the PCFT (gene code SLC46A1) and, to a lesser extent, by the reduced 16 
folate carrier (RFC, gene code SLC19A1), which has a lower affinity for folic acid [6]. Absorption 17 
across the intestinal epithelium is the limiting step for the availability of diet derived folates [7].  18 
 19 
Tissues with a high turnover rate like bone marrow, lymphatic tissue, hair follicles, and tumor cells are 20 
most susceptible to folate deficiencies [8]. During pregnancy, neural tube defects such as spina bifida, 21 
and in non-pregnant persons, anemia and pancytopenia, a reduced immune response and other 22 
pathologies may result. The total body folate store is thought to be 5-10 mg, of which 50% is contained 23 
in the liver. Since folate supply in a western-style diet is often not sufficient to cover the daily 24 
requirement of 200 – 400 µg, nutrition is also fortified with folic acid. Foods rich in folic acid include 25 
meat (e.g. liver), legumes (e.g. lentils, soy products), fruits and vegetables (e.g. fennel, nuts, spinach, 26 
broccoli, cabbage, beetroot, potato) and starches (wholegrain bread, wheat bran, rice).  27 
 28 
PCFT is an electrogenic transporter located in the apical enterocyte membrane of the proximal part of 29 
the small intestine and works best at low pH values [4, 9]. Mutations in the gene coding for PCFT were 30 
found in patients with hereditary folate malabsorption [10]. In cell culture experiments, it was shown 31 
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that the gene coding for PCFT is transactivated by the VDR and that rat duodenal Pcft mRNA levels 1 
as well as PCFT mRNA levels and folate uptake in Caco-2 cells were dose-dependently increased 2 
during treatment with 1,25(OH)2D3 [4].  3 
 4 
There are numerous other intestinal transporters for nutrients, ions, water, peptides and also 5 
xenobiotics. Two important representatives of the organic anion transporting polypeptide family, 6 
OATP1A2 (gene code SLCO1A2) and OATP2B1 (gene code SLCO2B1) are expressed in several 7 
tissues, notably at the blood brain barrier, in cholangiocytes, in the apical domain of tubular cells of the 8 
distal nephron and at the apical membrane of small intestinal epithelial cells. Although the expression 9 
level of OATP1A2 in human intestine is still controversial [11-13], OATP1A2 and OATP2B1 are 10 
responsible for the uptake of a number of drugs such as fexofenadine, rosuvastatin and atenolol, but 11 
also for the transport of endogenous substrates such as bile acids, conjugated sex steroids, thyroid 12 
hormones, prostaglandin E2 etc. On the other hand, apical and basolateral intestinal efflux transporters 13 
like P-glycoprotein (P-gp, gene code ABCB1) and multidrug-resistance related protein 3 (MRP3, gene 14 
code ABCC3), respectively, also exert influences on the absorption of drugs like fexofenadine [14]. In 15 
vitro data from our laboratory indicate that the expression of OATP1A2 is induced up to nine-fold by 16 
1,25(OH)2D3 [3], whereas nothing is known about an effect of 1,25(OH)2D3 on OATP2B1. Studies in 17 
vitro suggest that intestinal P-gp is upregulated by 1,25(OH)2D3 [15, 16], while reports on MRP3 are 18 
equivocal [15, 17].  19 
 20 
These in vitro findings suggest that intestinal folate uptake and uptake of OATP1A2 substrates can be 21 
increased by 1,25(OH)2D3. However, the extent to which these in vitro findings are relevant in vivo in 22 
humans is unknown. The aim of this study, therefore, was to investigate the influence of a sufficiently 23 
long 1,25(OH)2D3 administration on the pharmacokinetics of folic acid and fexofenadine as marker 24 
substrates of PCFT and OATP1A2 activities, respectively, in healthy human volunteers. To investigate 25 
the link between pharmacokinetics and transporter expression and activities, we additionally quantified 26 
mRNA of PCFT, OATP1A2, OATP2B1, P-gp and MRP3 in duodenal biopsies.  27 
  28 
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Methods  1 
 2 
Study design and population  3 
The study was performed as a prospective single arm, single center, pharmacokinetic study in 10 4 
healthy volunteers at the Department of Clinical Pharmacology and Toxicology, University Hospital of 5 
Zurich, Switzerland. Subjects were eligible if they were between 18 and 65 years of age, had a body 6 
mass index between 18 - 30 kg/m2 and were in a good healthy condition, as determined by physical 7 
examination and laboratory assessment conducted prior to the study. The intake of concomitant 8 
medication was not allowed, except oral contraceptives in women. Participants were instructed not to 9 
take in any nutrition supplement, especially folic acid or food fortified with folic acid.  10 
The study was approved by the Ethics Committee of the Canton of Zurich, Switzerland, (KEK-ZH-no. 11 
2012-0051) and by the Swiss National Health authority, Swissmedic. The clinicaltrials.gov identifier is 12 
NCT01856348. Written informed consent was obtained from each volunteer before any study related 13 
procedures were carried out. The study was carried out in accordance with the Declaration of Helsinki, 14 
amendment of Seoul, South Korea, 2008, and all pertinent guidelines and laws in force in Switzerland.  15 
 16 
Study procedures 17 
On study day one, 120 mg fexofenadine (Telfast®, Sanofi-Aventis, Meyrin, Switzerland), and on study 18 
day two, 5 mg folic acid (Acidum folicum Streuli®, Streuli, Uznach, Switzerland) was given to the 19 
participants orally together with 200 mL light sparkling water. An oesophago-gastro-duodenoscopy 20 
with biopsies from the duodenum to assess PCFT, OATP1A2, OATP2B1, P-gp and MRP3 mRNA 21 
expression was performed on study day one or two, depending on the availability of the endoscopy 22 
unit.  23 
During the following seven days (study days 3 to 10) participants were requested to take in 24 
1,25(OH)2D3 0.5 μg (Rocaltrol®, Roche Pharma, Reinach, Switzerland) daily in the morning at home 25 
and had to fill in a diary for treatment adherence, adverse event reporting and nutrition assessment. 26 
On study days eleven and twelve, a second dose of 120 mg fexofenadine and 5 mg folic acid, 27 
respectively, was given together with the daily dose of 1,25(OH)2D3, and a second endoscopy was 28 
carried out.  29 
All drug administrations on study days 1, 2, 11, and 12 were supervised by study personnel, and a 30 
mouth check was carried out. Before the study drug intakes on days 1, 2, 11, and 12, participants 31 
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fasted for at least 1 h. Subjects consumed a light breakfast after the 2 h blood sampling and a lunch at 1 
least 6 h after study drug intakes on the pharmacokinetics days.  2 
Serial blood samples to assess pharmacokinetics of fexofenadine (pre-dose and at 1, 2, 4, 6, 8, 10, 3 
and 24 h after fexofenadine intake) and folic acid (pre-dose and at 0.5, 1, 1.5, 2, 4, and 6 h after folic 4 
acid intake) were obtained on study days one (fexofenadine), two (folic acid), eleven (fexofenadine) 5 
and twelve (folic acid). Blood samples for the quantification of pre-dose 1,25(OH)2D3 serum 6 
concentrations were obtained on study days one, two, eleven and twelve.  7 
 8 
Sample analysis 9 
Blood samples were drawn from an indwelling catheter in the cubital vein and centrifuged at 4°C and 10 
3000 rpm for 10 minutes. The resulting serum was frozen at -80°C until analysis. Concentrations of 11 
folic acid and 1,25(OH)2D3 in serum were measured at the Institute of Clinical Chemistry of the 12 
University Hospital Zürich, Switzerland, and fexofenadine was analyzed by XenoGesis Ltd, 13 
Nottingham, UK.  14 
 15 
Quantification of folic acid in serum  16 
Folic acid was quantified in serum using a chemiluminescence immunoassay on the Access 2 17 
immunoanalyzer (Beckman Coulter, Brea, CA, USA). This test is standardized to the World Health 18 
Organization International Standard 03/178.  19 
In this assay, folic acid in the sample competes with a conjugate of folic acid and alkaline phosphatase 20 
for binding sites on a folic acid binding protein. After immobilization of the resulting complex on a solid 21 
phase and removal of unbound material, addition of a chemiluminescent substrate induces a light 22 
signal that is inversely proportional to the concentration of folic acid in the sample.  23 
The detection limit of this test is <1 µg/L and the limit of quantification <2 µg/L as indicated by the 24 
manufacturer. Inter- and intra-assay imprecision has been found to be lower than 10% for 25 
concentrations >3.6 µg/L. Since the dynamic measurement range of this test is between 1.0 and 24.8 26 
µg/L many of the samples had to be diluted to allow measurement of folic acid concentrations higher 27 
than 24.8 µg/L. As recommended by the manufacturer, the Access Folate Calibrator S0 (zero) was 28 
used for the dilutions.  29 
 30 
 31 
page 7 
 
Quantification of fexofenadine in serum  1 
Fexofenadine (FEX) and fexofenadine-d6 (FEX-d6) were purchased from Sequoia Research Products 2 
Ltd. (Pangbourne, UK) and Santa Cruz Biotechnology (Heidelberg, Germany), respectively. HPLC 3 
grade methanol and formic acid were from Fisher Scientific (Loughborough, UK). Water for HPLC was 4 
purified on a Milli Q system (Millipore, Watford, UK). 5 
FEX serum concentrations were assayed by LC-MS/MS using FEX-d6 as internal standard. FEX and 6 
FEX-d6 stock solutions were prepared at a concentration of 1 mg/ml in DMSO and stored at -20°C. 7 
Independent weighings were used for standards and quality controls (QC). Working solutions were 8 
prepared by dilution of stock solutions in methanol. Standards and QCs were prepared by spiking 10 9 
µl methanolic working solution into 50 µl blank human serum and adding 40 µl methanol plus 150 µl 10 
methanol containing 100 nM FEX-d6 as internal standard. Serum concentration curves were prepared 11 
at 2, 5, 10, 25, 50, 100, 250, 500, 1000 and 2000 ng/ml. QC samples were prepared in the same way 12 
containing 16, 160, 1600 ng/ml FEX.  13 
To each 50 µl serum sample 50 µl methanol and 150 µl methanol containing 100 nM FEX-d6 as 14 
internal standard were added. Blank serum samples were prepared in the same way. All samples, 15 
standards and QCs were vortex mixed and kept at -20°C for a minimum of 2 hours to allow complete 16 
protein precipitation. Samples were then centrifuged at 2500 x g, 4°C for 20 minutes, and 17 
supernatants were transferred for analysis by LC-MS/MS. 18 
Five µl of each sample were analysed in MRM mode on a Waters Premier XE tandem quadrupole 19 
mass spectrometer using electrospray ionisation and a Waters Acquity UPLC system (Waters Corp., 20 
Milford MA, USA). High performance liquid chromatography was performed on a ACE Excel 2 C18-21 
AR, 50 x 2.1mm column (ACE Ltd., Aberdeen, UK) using water (A) and methanol (B) both containing 22 
0.1 % v/v formic acid as mobile phases. Flow rate was 0.5 ml/minute, and the column temperature 23 
was 50°C. A solvent gradient was used: solvent B increased from 5% in the beginning to 95% at 1.5 24 
min, rose to 99% from 1.55 till 2 min, returned to 5% at 2.05 min and remained stable until the next 25 
injection started.  26 
MS/MS transitions were m/z 502.2 → 171.1 and 508.2 →177.1 for FEX and FEX-d6, respectively. 27 
Dwell time was 50 ms, cone voltage was 46 V and collision energy was 34 eV for both analytes. Peak 28 
area ratios of FEX and FEX-d6 were used for quantification. The lower and upper limits of 29 
quantification were 2 ng/ml and 2000 ng/ml, respectively. 30 
 31 
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Quantification of 1,25(OH)2D3 in serum  1 
After manual immunoextraction of 1,25(OH)2D3 from the serum sample using a monoclonal antibody, 2 
the concentration of this parameter was determined with a commercially available 1,25(OH)2D3 assay 3 
on an immunoanalyzer (IDS-iSYS immunoanalyzer, IDS plc, Boldon, UK) using a competitive 4 
immunoassay method. 1,25(OH)2D3 from the serum sample competed with a 1,25(OH)2D3-acridinium 5 
conjugate for binding to a biotinylated anti-1,25(OH)2D3-antibody. After immobilization and washing of 6 
the resulting antigen-antibody-complex, light signal induced by a chemiluminescence reaction was 7 
measured.  8 
Limit of detection of this test was 6.5 ng/L and limit of quantification, defined in accordance with the 9 
manufacturer’s recommendations as the concentration which can be measured with an inter-assay 10 
coefficient of variation not higher than 20%, was 12.2 ng/L. Measurement range of this test was 11 
between 6.5 and 210 ng/L (2), thus 1,25(OH)2D3 concentrations could be quantified in all samples 12 
without further dilution. Intra-assay imprecision has been found to be lower than 10% at concentrations 13 
of 37.9 and 82.3 ng/L (4.6 and 9.7%, respectively), inter-assay precision was 12.6% at 34.9 ng/L and 14 
11.9% at a 1,25(OH)2D3 concentration of 81.9 ng/L.  15 
 16 
Transporter mRNA quantification in duodenal biopsies  17 
Duodenal biopsies were immediately snap-frozen in liquid nitrogen and stored at -80ºC. Using the 18 
“Nucleospin miRNA” kit (Macherey-Nagel, Oensingen, Switzerland), frozen biopsies were immersed in 19 
the appropriate buffer and homogenized with a 1.5 mL pestle (VWR, Radnor, PA, USA), and RNA was 20 
extracted following the manufacturer’s instructions. Extracted RNA was subsequently analyzed by 21 
real-time PCR (RT-PCR) using TaqMan probes (Thermo Fisher, Waltham, MA, USA), and results 22 
were normalized to the enterocyte-specific housekeeping gene villin. Biopsies were identified 23 
according to subject (number) and whether they were collected before or after 1,25(OH)2D3 24 
administration. All mRNA quantifications were done in triplicate.  25 
 26 
Pharmacokinetic analysis  27 
A non-compartmental pharmacokinetic approach was chosen. The maximum serum concentration 28 
after drug intake (Cmax) and the time to reach Cmax (tmax) were directly taken from the plasma 29 
concentration-time data. The terminal elimination half-life (t1/2) was calculated by dividing ln(2) by the 30 
terminal elimination rate constant λz, which was estimated by linear regression of ln-concentration 31 
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data of the terminal part of the concentration-time curve. The area under the concentration-time curve 1 
(AUC) was calculated using the log-linear trapezoidal rule, either from the time of administration to a 2 
specified time point thereafter, or to the last quantifiable time point (AUC0-last). To obtain the AUC from 3 
administration extrapolated to infinity (AUC0-∞), the estimated AUClast-∞, which was calculated as Clast / 4 
λz, was added to AUC0-last. The parameters Cmax and AUC0-2 were selected for the characterization of 5 
the absorption phase of fexofenadine and folic acid.  6 
 7 
Statistical analysis 8 
Since the effect of a 1,25(OH)2D3 administration on the pharmacokinetics of fexofenadine and folic 9 
acid, respectively, has not yet been investigated in humans, the minimally relevant difference 10 
necessary for proper sample size calculation could not be estimated on a scientific basis. However, if 11 
an increase in exposure towards fexofenadine, or folic acid, of 50-80% is deemed relevant 12 
(corresponding to a “moderate” change in exposure according to FDA recommendations [18]), and if 13 
an inter-individual variability of roughly 20-30% is imputed (coefficients of variation in folic acid AUC0-∞ 14 
after a single oral dose of 5 mg were around 25% [19], and the coefficient of variation for fexofenadine 15 
AUC0-∞ after a single oral dose of 130 mg is reported to be 28.4% [20]), a sample size of 10 16 
participants would be sufficient to detect this difference with an α of 0.05 and a β of approximately 0.2. 17 
For the comparison of pharmacokinetics of fexofenadine and folic acid, respectively, before and after 18 
10 days of 1,25(OH)2D3 intake, an ANOVA-based relative bioequivalence assessment was carried out. 19 
The pharmacokinetic parameters of fexofenadine and folic acid before the start of intake of 20 
1,25(OH)2D3 were taken as reference for these calculations. Point estimates of the geometric means 21 
ratios of the pharmacokinetic parameters of fexofenadine and folic acid during 1,25(OH)2D3 intake 22 
over the pharmacokinetic parameters of fexofenadine and folic acid before the 1,25(OH)2D3 dosing 23 
period were calculated alongside with their corresponding 90% confidence intervals. An influence of 24 
1,25(OH)2D3 administration on the pharmacokinetics of fexofenadine, or folic acid, was accepted as 25 
absent if the 90% confidence intervals of the point estimates fell entirely within the bioequivalence 26 
zone of 0.8 – 1.25.  27 
 28 
  29 
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Results  1 
 2 
A total of 10 healthy volunteers (6 females, 4 males, mean age 26 ± 2 years, mean Body Mass Index 3 
22.9 ± 3.1 kg/m2, all non-smokers) were enrolled and completed the study. All adverse events were 4 
mild and transient. There was no statistically significant change in serum 1,25(OH)2D3 concentrations 5 
before and on the 11th and 12th day of vitamin D intake: the geometric mean 1,25(OH)2D3 6 
concentrations (geometric coefficient of variation) were as follows: day 1: 18.7 ng/mL (49%), day 2: 7 
19.1 ng/mL (48%), day 11: 20.9 ng/mL (44%), and day 12: 20.5 ng/mL (41%).  8 
 9 
Pharmacokinetics of folic acid and fexofenadine in serum before and after a ten-day course of oral 10 
1,25(OH)2D3 are shown in table 1 and 2, respectively. Folic acid concentrations in one participant were 11 
much lower in all samples taken after 1,25(OH)2D3 intake, which was implausible so that these 12 
volunteer’s data were excluded from the pharmacokinetic and statistical analysis for folic acid. Mean 13 
concentration-time curves as well as individual changes in total AUC and AUC0-2, a parameter mainly 14 
reflecting absorption, are shown for folic acid and fexofenadine in fig. 1 and 2, respectively. In 15 
summary, folic acid pharmacokinetics were not statistically significantly different after ten days of 16 
1,25(OH)2D3 intake (table 1). For fexofenadine pharmacokinetics, statistically significant changes were 17 
also not observed (table 2). Although the parameters of fexofenadine best reflecting absorption, i.e. 18 
Cmax and AUC0-2, showed mean increases by 31 and 43%, respectively, the interindividual variabilities 19 
were too large to yield significant findings.  20 
 21 
The villin-normalized mRNA contents of PCFT, OATP1A2 and OATP2B1 in the duodenal biopsies 22 
taken before and at the end of a 10-days course of 1,25(OH)2D3 are shown in fig. 3. OATP1A2 mRNA 23 
could not be quantified in 4 samples from 3 volunteers. OATP2B1-, PCFT-, P-gp and MRP3-mRNA 24 
was quantifiable in all biopsy samples. In an ANOVA-based evaluation, there was no statistically 25 
significant difference in geometric mean villin-normalized mRNA content of any of the transporters 26 
between the two biopsy time points, except for MRP3, where a marginally significant decrease in 27 
mRNA was observed. For OATP1A2, the geometric mean relative villin-normalized mRNA contents 28 
was 0.811 in biopsies taken before, and 0.727 in biopsies taken after ten days of 1,25(OH)2D3 intake 29 
(geometric means ratio (GMR): 89.66, 90% confidence interval (90%CI): 65.87 – 122.03). For 30 
OATP2B1, the geometric mean mRNA contents were 1.149 before and 1.146 after the ten days 31 
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course (GMR: 99.75, 90%CI: 98.96 – 100.54), and for PCFT, values were 0.997 before and 0.996 1 
after the 1,25(OH)2D3 intake (GMR: 99.99, 90%CI: 99.16 – 100.84). For the efflux transporter P-gp, 2 
the geometric mean mRNA contents were 1.860 before and 1.608 after the 1,25(OH)2D3 intake (GMR: 3 
86.41, 90%CI: 72.01 – 103.70), and corresponding values for MRP3 were 2.988 and 2.724 (GMR: 4 
91.15, 90% CI: 83.65 – 99.33).  5 
 6 
  7 
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Discussion  1 
 2 
This study aimed at clarifying whether an inducing effect of 1,25(OH)2D3 on folate uptake via PCFT 3 
could be confirmed in vivo in humans, as well as on the transport capacity of OATP1A2 and 4 
OATP2B1, because inducing effects on PCFT and OATP1A2 have been demonstrated in cell culture 5 
experiments [3, 4]. We could rule out that a ten days’ course of 1,25(OH)2D3 has an effect on folate 6 
uptake and on PCFT expression in healthy human volunteers. Although the mean results for 7 
fexofenadine favored an increase in fexofenadine uptake of about 30-40% after ten days of 8 
1,25(OH)2D3, these results were not statistically significant and the intestinal mRNA expression of 9 
OATP1A2 and OATP2B1 was not changed.  10 
 11 
Two intestinal uptake mechanisms exist for folates in humans. While the PCFT is the most relevant 12 
transport mechanism, the RFC does not seem to play an important role in folate uptake in the 13 
intestines [6]. As experiments from our group have shown earlier, PCFT can be dose-dependently 14 
trans-activated by binding of 1,25(OH)2D3 to a VDR-RXR heterodimer, which then binds to the PCFT 15 
promoter and roughly doubles PCFT expression and folate uptake in Caco-2 cells in vitro [4]. 16 
However, the present study shows that this effect is not quantifiable in vivo. In a post-hoc evaluation of 17 
a study which investigated the effects of different vitamin D supplementations on 25-hydroxyvitamin D 18 
(25(OH)D) concentrations in humans, others have recently found out that, although 25(OH)D 19 
concentrations rose after an 8-week supplementation course, no differences in folic acid plasma 20 
concentrations could be substantiated [21]. In our present study, we did not find an effect on PCFT 21 
mRNA expression in intestinal biopsies, which corroborates the absence of an effect of 1,25(OH)2D3 22 
on folic acid absorption in vivo in humans. These results underline the importance of verifying in vitro 23 
findings by in vivo studies, although the explanations for the observed discrepancies are not obvious. 24 
It can be speculated that the 1,25(OH)2D3 concentration changes in the enterocytes (and the 25 
1,25(OH)2D3 doses used) were too low to lead to a quantifiable effect on PCFT expression and 26 
activity. In vitro, a 3-day treatment with only 25 nM 1,25(OH)2D3 (corresponding to approx. 10 µg/L) 27 
was sufficient to show a significant PCFT mRNA increase in Caco-2 cells, but more pronounced 28 
effects were seen with 100 – 200 µg/L 1,25(OH)2D3 [4]. Trough serum concentrations (taken 24 h after 29 
the last intake) of at least 10 µg/L were present in 9 out of the 10 volunteers already at the start of the 30 
study and, as expected, did not change throughout the study. This finding is in line with the fact that 31 
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1,25(OH)2D3 serum concentrations are tightly controlled in the human body. It may be possible that 1 
higher doses would have led to a quantifiable effect. However, since higher doses of 1,25(OH)2D3 may 2 
confer an undue risk for prolonged hypercalcemia and related adverse effects, we did not select higher 3 
doses for the present study.  4 
 5 
Most drugs which are absorbed from the intestine via drug transporters are not specific substrates for 6 
a single transporter. This is also the case with fexofenadine, which is taken up from the gut lumen by 7 
OATP1A2 and OATP2B1 [22], and is transported outwards towards the gut lumen by P-gp [23], while 8 
MRP3-mediated transport is directed towards the portal blood [13]. It is therefore not directly possible 9 
to unequivocally identify the mechanisms that ultimately determine absorption pharmacokinetics of 10 
fexofenadine after a ten days’ course of 1,25(OH)2D3. OATP1A2 has been shown to be upregulated in 11 
vitro up to 9-fold by a three-day treatment of Caco-2 cells with a large dose of 500 nM (approx. 200 12 
µg/L) 1,25(OH)2D3 for 24 hours [3]. Additionally, it was also shown that P-gp mRNA and protein 13 
expression was increased in Caco-2 cells after 24 h treatment with 100 nM 1,25(OH)2D3, and that this 14 
effect diminished with time [15]. In vitro studies on the effect of 1,25(OH)2D3 on MRP3 led to 15 
contradictory results [15, 17]. The marginally significant decrease in MRP3 mRNA we observed here 16 
would even suggest a decrease in fexofenadine bioavailability, but the small extent of the change 17 
does not suggest any relevance. Since there is still controversy whether OATP1A2 is expressed in 18 
human intestine (we observed OATP1A2 mRNA in 16 out of 20 duodenal biopsies), since nothing is 19 
known about the inducibility of OATP2B1 by 1,25(OH)2D3, and since we did not observe any relevant 20 
changes in the duodenal mRNA of the four transporters involved in fexofenadine pharmacokinetics, 21 
there is no mechanistic explanation which would support the non-significant trend towards slightly 22 
higher mean fexofenadine exposure after a ten-day treatment with 1,25(OH)2D3 observed in the 23 
present study in healthy volunteers. Taken together, a ten days course of 1,25(OH)2D3 does not lead 24 
to major changes in fexofenadine pharmacokinetics and in duodenal mRNA of OATP1A2, OATP2B1, 25 
P-gp and MRP3.  26 
 27 
Some limitations of this study have to be considered. First, we investigated healthy volunteers whose 28 
1,25(OH)2D3 concentrations were at the lower range of normal, but who did not have manifest vitamin 29 
D deficiency. This may have prevented an effect of 1,25(OH)2D3 on folic acid pharmacokinetics 30 
becoming quantifiable. Second, a ten days’ course of 1,25(OH)2D3 may have been too short to lead to 31 
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substantial effects, although the induction was statistically significant in cell culture already after a 1 
three-day treatment. Higher 1,25(OH)2D3 doses may have led to a visible effect on folic acid 2 
absorption and a statistically significant effect on fexofenadine pharmacokinetics. Last, since the 3 
variability in fexofenadine pharmacokinetics was higher than expected, a larger number of participants 4 
would have been necessary to unequivocally answer the question whether fexofenadine transport is 5 
significantly affected by 1,25(OH)2D3 treatment.  6 
 7 
In summary, we show that a ten-day course of usual doses of 1,25(OH)2D3 does neither affect folic 8 
acid uptake nor fexofenadine pharmacokinetics in a significant manner. The results of this study 9 
underscore the importance of investigating whether in vitro findings can be confirmed in vivo.  10 
 11 
  12 
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Legends to figures  1 
 2 
Figure 1: Mean folic acid serum concentration-time curves (a), AUC0-last (b) and AUC0-2 (c) before 3 
(circles) and after (diamonds) a ten day course of 0.5 μg of 1,25(OH)2D3 daily intake in ten healthy 4 
male and female volunteers.  5 
 6 
Figure 2: Mean fexofenadine concentration-time curves (a), AUC0-last (b) and AUC0-2 (c) before (circles) 7 
and after (diamonds) a ten day course of 0.5 μg of 1,25(OH)2D3 daily intake in ten healthy male and 8 
female volunteers.  9 
 10 
Figure 3: Villin-normalized PCFT (a) OATP1A2 (b) and OATP2B1 (c) mRNA levels in duodenal 11 
biopsies taken before and on the 9th or 10th day of (after) a ten day course of 0.5 μg of 1,25(OH)2D3 12 
daily intake in ten healthy male and female volunteers.  13 
 14 
  15 
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Table 1: Pharmacokinetics of folic acid in 9 healthy volunteers before and after a 10-day course of 1 
1,25(OH)2D3. Pharmacokinetic parameters are shown as geometric means (geometric coefficient of 2 
variation) for concentration-dependent parameters, and as arithmetic mean (standard deviation) for 3 
tmax and t1/2. n.c.= not calculated.  4 
 5 
 Before 1,25(OH)2D3 After 1,25(OH)2D3  Geometric mean 
ratio  
90 % confidence 
interval  
AUC0-6 [µg/L*h]  1465.5 (20.1%)  1506.9 (34.7%)  102.8 86.4 – 122.4 
AUC0-∞ [µg/L*h] 2007.4 (24.8%) 1967.6 (39.1%)  98.0 82.7 – 116.2 
AUC0-2 [µg/L*h]  403.1 (35.6%)  414.0 (29.6%)  102.7 78.8 – 134.0 
Cmax [µg/L]  407.7 (16.9%)  416.8 (32.9%)  102.2 83.9 – 124.5 
tmax [h] 1.9 (0.8) 1.9 (0.2) n.c. n.c. 
t1/2 [h]  2.7 (0.5) 2.5 (0.6) n.c. n.c. 
 6 
  7 
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Table 2: Pharmacokinetics of fexofenadine in 10 healthy volunteers before and after a 10-day course 1 
of 1,25(OH)2D3. Pharmacokinetic parameters are shown as geometric means (geometric coefficient of 2 
variation) for concentration-dependent parameters, and as arithmetic mean (standard deviation) for 3 
tmax and t1/2. n.c.= not calculated.  4 
 5 
 Before 1,25(OH)2D3 After 1,25(OH)2D3  Geometric mean 
ratio  
90 % confidence 
interval  
AUC0-24 [µg/L*h]  1263.8 (75.8 %)  1474.9 (30.5 %)  116.7 78.4 – 173.8 
AUC0-∞ [µg/L*h] 1313.6 (73.9 %)  1521.3 (29.9 %)  115.8 78.4 – 171.0 
AUC0-2 [µg/L*h]  193.2 (91.2 %)  276.1 (45.9%)  142.9 89.0 – 229.4 
Cmax [µg/L]  169.8 (90.1 %)  222.5 (40.7 %)  131.0 82.1 – 209.1 
tmax [h] 1.9 (1.4) 2.1 (1.0) n.c. n.c. 
t1/2 [h]  5.2 (0.8)  4.9 (0.7)  n.c. n.c. 
 6 
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Figure 1: Mean folic acid serum concentration-time curves (a), AUC0-last (b) and AUC0-2 (c) before 1 
(circles) and after (diamonds) a ten day course of 0.5 μg of 1,25(OH)2D3 daily intake in ten healthy 2 
male and female volunteers.  3 
 4 
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Figure 2: Mean fexofenadine concentration-time curves (a), AUC0-last (b) and AUC0-2 (c) before (circles) 1 
and after (diamonds) a ten day course of 0.5 μg of 1,25(OH)2D3 daily intake in ten healthy male and 2 
female volunteers. 3 
 4 
a)  5 
 6 
 7 
b)  8 
 9 
 10 
c)  11 
page 24 
 
 1 
  2 
page 25 
 
Figure 3: Villin-normalized PCFT (a) OATP1A2 (b) and OATP2B1 (c) mRNA levels in duodenal 1 
biopsies taken before and on the 9th or 10th day of (after) a ten day course of 0.5 μg of 1,25(OH)2D3 2 
daily intake in ten healthy male and female volunteers.  3 
 4 
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b) 8 
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